

Hello there,

We’re pleased to announce that the latest LabGx system updates are now live and available for use. This release includes several new features and enhancements designed to provide greater reporting flexibility and further streamline your workflows.

 **Meet us at [AMP 2025](#) in Boston from November 11-15! If you'll be there, we'd love to see you. Email sales@genxys.com to set up a meeting.**

New Features:

New LabGx report section for Medications Being Considered

LabGx now includes a dedicated section for Medications Being Considered, allowing labs to upload and display medications that are under review for a patient, similar to how current medications are managed. This enhancement enables users to view drug–gene and drug–drug interactions for both current and considered medications directly within the report.


Considered medications are clearly distinguished from current medications through separate visual representations, ensuring easy interpretation and clarity within the report.

Medications Being Considered				
Clopidogrel	Phenotype	Genetic Test	Results	Source/Evidence Level
Plavix TreatGx ReviewGx	Intermediate metabolizer	CYP2C19	*2/*38	CPIC A ²⁸ ; FDA 1 ⁴⁶
Drug-Gene Interactions:				
Serious drug-gene interaction: avoid/select alternative				
 CPIC – Implication: Reduced clopidogrel active metabolite formation; increased on-treatment platelet reactivity; increased risk for adverse cardiac and cerebrovascular events.				
 CPIC – Strong Recommendation for acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI): Avoid standard dose clopidogrel (75 mg) if possible. Use prasugrel or ticagrelor at standard dose if no contraindication. No recommendation for non-ACS, non-PCI cardiovascular indications. ACS and/or PCI includes patients undergoing PCI for an ACS or non-ACS (elective) indication. Non-ACS, non-PCI cardiovascular indications include peripheral arterial disease and stable coronary artery disease following a recent myocardial infarction outside the setting of PCI.				
Drug-Drug Interactions:				
 (Acetaminophen)-(Clopidogrel) The metabolism of Clopidogrel can be decreased when combined with Acetaminophen.				

In addition, the JSON order structure has been updated to support considered medications. Both *current* and *considered* medications can now be submitted together in a single order. For full details, please refer to the updated documentation: [Order Specification v1.11](#).

Lab Studio PDF Setup Wizard

A new wizard companion has been added to Lab Studio to help users navigate the report setup process with ease. The wizard provides step-by-step guidance through various customization options and includes helpful descriptions to support a smoother and more intuitive configuration experience.



Latest Updates:

- Current Medications will display in order of the most severe drug-gene interactions to the least.
- Current Medications will always display even if they are filtered out in rest of the report with a message that there are no drug-gene interactions for that selected content.
- Email notifications will be sent when the current medications submitted do not find a match in the system. The notification can be set up from LabStudio.

For any questions or further assistance, please get in touch with us at info@genxys.com.
Thank you for your continued support and feedback!

All the best,
GenXys Team